Cellectricon will present a novel phenotypic assay at World Pharma Congress 2013, Tues 4th June, 5pm
Molndal, Sweden 29 May 2013 Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be attending the 12th annual World Pharma Congress, 4 6 June (Philadelphia, PA). At the event, Cellectricon¹s Head of Discovery Services, Dr Paul Karila, will host a presentation describing a novel phenotypic assay for the identification of therapeutic compounds for chronic pain. The talk, entitled ŒDevelopment of a Phenotypic Pain Assay for Identification of Modulators of Excitability in Native Sensory Neurons¹, will take place on Tues 4th June, 5pm, as part of the ŒTargeting Pain with Novel Therapeutics¹program. This exciting new assay is based on the Cellaxess® technology platform, and uses electric field stimulation of primary DRG neuronal cultures to allow compound identification during early stages of the project lifecycle. As such, Dr Karila will explain how the approach can add significant value to the overall decision-making process of drug development, saving valuable time and cost. Dr Paul Karila is Chairperson for the ŒTargeting Pain with Novel Therapeutics¹ program, and will be on-hand throughout the day to answer any questions on Cellectricon¹s services and technology. Alternatively, for more information on Cellectricon, please visit www.cellectricon.com
About Cellectricon
Cellectricon provides state-of-the-art discovery services and enabling technologies to accelerate drug discovery and cell-based research. Our compound profiling services in excitable cells and native tissue provide researchers with decision-making insight into the science of cytoskeletal disturbances, particularly focusing on chronic pain
Office 3
Universal Marina
Crableck Lane
Sarisbury Green
Southampton
SO31 7AL
T +44 (0) 1489 557672
E: [email protected] www.alto-marketing.com